|
US20060165606A1
(en)
|
1997-09-29 |
2006-07-27 |
Nektar Therapeutics |
Pulmonary delivery particles comprising water insoluble or crystalline active agents
|
|
EP1767195A3
(de)
*
|
1998-08-25 |
2007-04-04 |
Advanced Inhalation Research, Inc. |
Stabile sprühgetrocknete Proteinformulierungen
|
|
JP4874483B2
(ja)
|
1999-06-09 |
2012-02-15 |
ロバート イー． シーバース |
超臨界流体補助ネブライゼーション及びバブル乾燥
|
|
US6858199B1
(en)
*
|
2000-06-09 |
2005-02-22 |
Advanced Inhalation Research, Inc. |
High efficient delivery of a large therapeutic mass aerosol
|
|
AU763041B2
(en)
*
|
1999-08-25 |
2003-07-10 |
Alkermes, Inc. |
Modulation of release from dry powder formulations
|
|
US7229619B1
(en)
|
2000-11-28 |
2007-06-12 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
|
US7871598B1
(en)
|
2000-05-10 |
2011-01-18 |
Novartis Ag |
Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
|
|
US7179900B2
(en)
|
2000-11-28 |
2007-02-20 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
|
US6818216B2
(en)
|
2000-11-28 |
2004-11-16 |
Medimmune, Inc. |
Anti-RSV antibodies
|
|
US6855493B2
(en)
|
2000-11-28 |
2005-02-15 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
|
EP2412384A1
(de)
|
2000-11-28 |
2012-02-01 |
MedImmune, LLC |
Verfahren zur Verabreichung/Dosierung von Anti-RSV-Antikörpern zur Prophylaxe und Behandlung
|
|
DE60143544D1
(de)
|
2000-12-12 |
2011-01-05 |
Medimmune Llc |
Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
|
|
GB0208742D0
(en)
|
2002-04-17 |
2002-05-29 |
Bradford Particle Design Ltd |
Particulate materials
|
|
MXPA04005865A
(es)
|
2001-12-19 |
2004-09-13 |
Nektar Therapeutics |
Suministro de aminoglucosidos a los pulmones.
|
|
US7138136B2
(en)
*
|
2002-03-05 |
2006-11-21 |
Cleveland State University |
Agglomerated particles for aerosol drug delivery
|
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
|
US7425620B2
(en)
|
2002-08-14 |
2008-09-16 |
Scott Koenig |
FcγRIIB-specific antibodies and methods of use thereof
|
|
DE60336406D1
(de)
|
2002-10-16 |
2011-04-28 |
Purdue Pharma Lp |
Antikörper, die an zellassoziiertes ca 125/0722p binden, und verfahren zu deren anwendung
|
|
ES2897506T3
(es)
|
2003-01-09 |
2022-03-01 |
Macrogenics Inc |
Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de utilización de los mismos
|
|
US7700100B2
(en)
|
2003-01-13 |
2010-04-20 |
Macrogenics, Inc. |
FcγRIIB fusion proteins and compositions thereof
|
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
|
JP4707937B2
(ja)
*
|
2003-02-28 |
2011-06-22 |
ホソカワミクロン株式会社 |
薬物含有複合粒子の製造方法および経肺製剤
|
|
WO2004091510A2
(en)
|
2003-04-11 |
2004-10-28 |
Medimmune, Inc. |
Recombinant il-9 antibodies and uses thereof
|
|
JP4934426B2
(ja)
|
2003-08-18 |
2012-05-16 |
メディミューン，エルエルシー |
抗体のヒト化
|
|
US7371381B2
(en)
|
2003-12-12 |
2008-05-13 |
Amgen Inc. |
Anti-galanin antibodies and uses thereof
|
|
EP1701714A2
(de)
*
|
2004-01-07 |
2006-09-20 |
Nektar Therapeutics |
Verbesserte zusammensetzungen mit verzögerter freisetzung für die pulmonale verabreichung von insulin
|
|
WO2005092301A1
(en)
|
2004-03-26 |
2005-10-06 |
Universita' Degli Studi Di Parma |
Insulin highly respirable microparticles
|
|
US7723306B2
(en)
|
2004-05-10 |
2010-05-25 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
|
|
US7727962B2
(en)
|
2004-05-10 |
2010-06-01 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Powder comprising new compositions of oligosaccharides and methods for their preparation
|
|
US7611709B2
(en)
|
2004-05-10 |
2009-11-03 |
Boehringer Ingelheim Pharma Gmbh And Co. Kg |
1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
|
|
CA2580921C
(en)
|
2004-09-21 |
2016-04-12 |
Medimmune, Inc. |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
|
EP1869192B1
(de)
|
2005-03-18 |
2016-01-20 |
MedImmune, LLC |
Rahmenmischung von antikörpern
|
|
US9889197B2
(en)
|
2005-04-15 |
2018-02-13 |
Macrogenics, Inc. |
Covalently-associated diabody complexes that possess charged coil domains and that are capable of enhanced binding to serum albumin
|
|
AU2006236439B2
(en)
|
2005-04-15 |
2012-05-03 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
|
US20070110757A1
(en)
|
2005-06-23 |
2007-05-17 |
Ziping Wei |
Antibody formulations having optimized aggregation and fragmentation profiles
|
|
WO2007021841A2
(en)
|
2005-08-10 |
2007-02-22 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant fc regions and methods of using same
|
|
EP2500356A3
(de)
|
2005-08-19 |
2012-10-24 |
Abbott Laboratories |
Immunglobuline mit zweifacher variabler Domäne und ihre Verwendung
|
|
EP2495257A3
(de)
|
2005-08-19 |
2012-10-17 |
Abbott Laboratories |
Immunglobuline mit zweifacher variabler Domäne und ihre Verwendung
|
|
US8906864B2
(en)
|
2005-09-30 |
2014-12-09 |
AbbVie Deutschland GmbH & Co. KG |
Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
|
|
ITMI20051999A1
(it)
|
2005-10-21 |
2007-04-22 |
Eratech S R L |
Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
|
|
DK1976877T4
(en)
|
2005-11-30 |
2017-01-16 |
Abbvie Inc |
Monoclonal antibodies to amyloid beta protein and uses thereof
|
|
PL1954718T3
(pl)
|
2005-11-30 |
2015-04-30 |
Abbvie Inc |
Przeciwciała skierowane przeciwko A globulomerowi, ich reszty wiążące antygeny, odpowiednie hybrydomy, kwasy nukleinowe, wektory, komórki gospodarze, sposoby wytwarzania tych przeciwciał, kompozycje zawierające te przeciwciała, zastosowania tych przeciwciał i sposoby stosowania tych przeciwciał
|
|
JP5115951B2
(ja)
*
|
2006-03-17 |
2013-01-09 |
学校法人東京理科大学 |
ナノコンポジット粒子
|
|
ES2599319T3
(es)
|
2006-06-26 |
2017-02-01 |
Macrogenics, Inc. |
Anticuerpos específicos de Fc RIIB y métodos de uso de éstos
|
|
US8058402B2
(en)
|
2006-08-28 |
2011-11-15 |
Kyowa Hakko Kirin |
Antagonistic human LIGHT-specific human monoclonal antibodies
|
|
US7915388B2
(en)
|
2006-09-08 |
2011-03-29 |
Abbott Laboratories |
Interleukin-13 binding proteins
|
|
WO2008048545A2
(en)
|
2006-10-16 |
2008-04-24 |
Medimmune, Llc. |
Molecules with reduced half-lives, compositions and uses thereof
|
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
|
ES2691033T3
(es)
|
2007-02-11 |
2018-11-23 |
Map Pharmaceuticals Inc. |
Método de administración terapéutica de DHE para activar el alivio rápido de la migraña a la vez que se reduce al mínimo el perfil de los efectos secundarios
|
|
US20100311767A1
(en)
|
2007-02-27 |
2010-12-09 |
Abbott Gmbh & Co. Kg |
Method for the treatment of amyloidoses
|
|
EP2164868B1
(de)
|
2007-05-04 |
2015-03-25 |
Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA |
Gentechnisch gewonnene variable domänen von kaninchen-antikörpern und deren verwendung
|
|
EP1997830A1
(de)
|
2007-06-01 |
2008-12-03 |
AIMM Therapeutics B.V. |
RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung
|
|
AU2008265984B2
(en)
|
2007-06-21 |
2014-07-17 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
|
EP2069401A4
(de)
|
2007-07-31 |
2011-02-23 |
Medimmune Llc |
Multispezifische epitop-bindende proteine und ihre verwendung
|
|
EP2244729B1
(de)
|
2008-01-18 |
2016-11-02 |
MedImmune, LLC |
Cystein-manipulierte antikörper zur stellenspezifischen konjugation
|
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
|
EP2282769A4
(de)
|
2008-04-29 |
2012-04-25 |
Abbott Lab |
Dual-variable- domain-immunglobuline und ihre verwendungen
|
|
EP2500361B1
(de)
|
2008-05-09 |
2016-03-30 |
AbbVie Deutschland GmbH & Co KG |
Antikörper zu Rezeptor für Endprodukte der fortgeschrittenen Glykierung (RAGE) und Verwendungen davon
|
|
JP5723769B2
(ja)
|
2008-06-03 |
2015-05-27 |
アッヴィ・インコーポレイテッド |
二重可変ドメイン免疫グロブリン及びその使用
|
|
EP2297209A4
(de)
|
2008-06-03 |
2012-08-01 |
Abbott Lab |
Dual-variable- domain-immunglobuline und ihre verwendungen
|
|
SG192496A1
(en)
|
2008-07-08 |
2013-08-30 |
Abbott Lab |
Prostaglandin e2 binding proteins and uses thereof
|
|
EP2321422A4
(de)
|
2008-07-08 |
2013-06-19 |
Abbvie Inc |
Prostaglandin-e2-immunglobuline mit doppelter variabler domäne und verwendungen davon
|
|
BRPI0918122A8
(pt)
|
2008-12-19 |
2017-01-24 |
Macrogenics Inc |
molécula de diabody, diabody, e mólecula dart
|
|
WO2010087927A2
(en)
|
2009-02-02 |
2010-08-05 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
|
US8030026B2
(en)
|
2009-02-24 |
2011-10-04 |
Abbott Laboratories |
Antibodies to troponin I and methods of use thereof
|
|
RU2015132478A
(ru)
|
2009-03-05 |
2015-12-10 |
Эббви Инк. |
Связывающие il-17 белки
|
|
US8283162B2
(en)
|
2009-03-10 |
2012-10-09 |
Abbott Laboratories |
Antibodies relating to PIVKAII and uses thereof
|
|
WO2010141329A1
(en)
|
2009-06-01 |
2010-12-09 |
Medimmune, Llc |
Molecules with extended half-lives and uses thereof
|
|
MX2012000121A
(es)
|
2009-06-22 |
2012-03-07 |
Medimmune Llc |
Regiones fc modificadas para la conjugacion especifica del sitio.
|
|
EP2464664B1
(de)
|
2009-08-13 |
2015-09-23 |
Crucell Holland B.V. |
Antikörper gegen humanes respiratorisches syncytialvirus und anwendungsverfahren
|
|
CN102741288B
(zh)
|
2009-08-29 |
2015-08-19 |
Abbvie公司 |
治疗用dll4结合蛋白
|
|
SG178602A1
(en)
|
2009-09-01 |
2012-04-27 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
US20110189183A1
(en)
|
2009-09-18 |
2011-08-04 |
Robert Anthony Williamson |
Antibodies against candida, collections thereof and methods of use
|
|
US8568726B2
(en)
|
2009-10-06 |
2013-10-29 |
Medimmune Limited |
RSV specific binding molecule
|
|
AU2010303415B2
(en)
|
2009-10-07 |
2015-02-19 |
Macrogenics, Inc. |
Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
|
|
WO2011047262A2
(en)
|
2009-10-15 |
2011-04-21 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
WO2011053707A1
(en)
|
2009-10-31 |
2011-05-05 |
Abbott Laboratories |
Antibodies to receptor for advanced glycation end products (rage) and uses thereof
|
|
ES2562832T3
(es)
|
2009-12-08 |
2016-03-08 |
Abbvie Deutschland Gmbh & Co Kg |
Anticuerpos monoclonales contra la proteína RGM para su uso en el tratamiento de la degeneración de la capa de fibra nerviosa de la retina
|
|
JP5964249B2
(ja)
|
2010-03-02 |
2016-08-03 |
アッヴィ・インコーポレイテッド |
治療用ｄｌｌ４結合タンパク質
|
|
SG10201504808XA
(en)
|
2010-03-17 |
2015-07-30 |
Abbott Res Bv |
Anti-Nerve Growth Factor (NGF) Antibody Compositions
|
|
JP2013523182A
(ja)
|
2010-04-15 |
2013-06-17 |
アボット・ラボラトリーズ |
アミロイドベータ結合タンパク質
|
|
US9290573B2
(en)
|
2010-05-06 |
2016-03-22 |
Novartis Ag |
Therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies
|
|
JP2013527762A
(ja)
|
2010-05-06 |
2013-07-04 |
ノバルティス アーゲー |
治療的低密度リポタンパク質関連タンパク質６（ｌｒｐ６）抗体の組成物および使用方法
|
|
AR081246A1
(es)
|
2010-05-14 |
2012-07-18 |
Abbott Lab |
Proteinas de union a il-1
|
|
BR112012033121B1
(pt)
|
2010-06-25 |
2019-08-20 |
Institut Pasteur De Lille |
Métodos e composições farmacêuticas para o tratamento de infecções do trato respiratório.
|
|
WO2012006500A2
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
NZ703035A
(en)
|
2010-07-09 |
2016-06-24 |
Crucell Holland Bv |
Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
|
|
US9120862B2
(en)
|
2010-07-26 |
2015-09-01 |
Abbott Laboratories |
Antibodies relating to PIVKA-II and uses thereof
|
|
JP2013537415A
(ja)
|
2010-08-03 |
2013-10-03 |
アッヴィ・インコーポレイテッド |
二重可変ドメイン免疫グロブリンおよびその使用
|
|
EP2603524A1
(de)
|
2010-08-14 |
2013-06-19 |
AbbVie Inc. |
Amyloid-beta-bindende proteine
|
|
ES2665954T3
(es)
|
2010-08-19 |
2018-04-30 |
Zoetis Belgium S.A. |
Anticuerpos anti-NGF y su uso
|
|
MX2013002046A
(es)
|
2010-08-20 |
2013-04-03 |
Novartis Ag |
Anticuerpos para el receptor del factor de crecimiento epidermico 3 (her3).
|
|
GB201013989D0
(en)
|
2010-08-20 |
2010-10-06 |
Univ Southampton |
Biological materials and methods of using the same
|
|
CA2809433A1
(en)
|
2010-08-26 |
2012-03-01 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
US20130245233A1
(en)
|
2010-11-24 |
2013-09-19 |
Ming Lei |
Multispecific Molecules
|
|
BR112013015944A2
(pt)
|
2010-12-21 |
2018-06-19 |
Abbvie Inc |
imunoglobulinas de domínio duplo variável il-1 alpha e beta biespecífico e seus usos.
|
|
WO2012088094A2
(en)
|
2010-12-21 |
2012-06-28 |
Abbott Laboratories |
Il-1 binding proteins
|
|
EP2699264B1
(de)
|
2011-04-20 |
2018-03-14 |
Medlmmune, LLC |
Antikörper und andere moleküle zur bindung von b7-h1 und pd-1
|
|
SG195073A1
(en)
|
2011-05-21 |
2013-12-30 |
Macrogenics Inc |
Deimmunized serum-binding domains and their use for extending serum half-life
|
|
KR20140061403A
(ko)
|
2011-07-13 |
2014-05-21 |
애브비 인코포레이티드 |
항―ｉｌ―１３ 항체를 이용하여 천식을 치료하기 위한 방법 및 조성물
|
|
WO2013010955A1
(en)
|
2011-07-15 |
2013-01-24 |
Morphosys Ag |
Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
|
|
JP6120848B2
(ja)
|
2011-08-15 |
2017-04-26 |
メディミューン，エルエルシー |
抗ｂ７−ｈ４抗体およびその使用
|
|
MX2014004977A
(es)
|
2011-10-24 |
2014-09-11 |
Abbvie Inc |
Inmunoaglutinantes dirigidos contra esclerostina.
|
|
ES2758433T3
(es)
|
2011-12-05 |
2020-05-05 |
Novartis Ag |
Anticuerpos contra el receptor 3 del factor de crecimiento epidérmico (HER3)
|
|
CA2857601A1
(en)
|
2011-12-05 |
2013-06-13 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
|
|
CA2855570A1
(en)
|
2011-12-14 |
2013-06-20 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
|
JP6342812B2
(ja)
|
2011-12-14 |
2018-06-13 |
アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー |
鉄関連障害を診断および治療するための組成物および方法
|
|
ES2721882T3
(es)
|
2011-12-23 |
2019-08-06 |
Pfizer |
Regiones constantes de anticuerpo modificadas por ingeniería genética para conjugación específica de sitio y procedimientos y usos de las mismas
|
|
US9120870B2
(en)
|
2011-12-30 |
2015-09-01 |
Abbvie Inc. |
Dual specific binding proteins directed against IL-13 and IL-17
|
|
CN107880124B
(zh)
|
2012-01-27 |
2021-08-13 |
艾伯维德国有限责任两合公司 |
用于诊断和治疗与神经突变性相关的疾病的组合物和方法
|
|
US9603906B2
(en)
|
2012-02-01 |
2017-03-28 |
Protalix Ltd. |
Inhalable liquid formulations of DNase I
|
|
EP2855520B1
(de)
|
2012-06-04 |
2018-09-26 |
Novartis AG |
Verfahren zur stellenspezifischen markierung und dadurch hergestellte moleküle
|
|
WO2013184871A1
(en)
|
2012-06-06 |
2013-12-12 |
Zoetis Llc |
Caninized anti-ngf antibodies and methods thereof
|
|
US9670276B2
(en)
|
2012-07-12 |
2017-06-06 |
Abbvie Inc. |
IL-1 binding proteins
|
|
BR112015009961B1
(pt)
|
2012-11-01 |
2020-10-20 |
Abbvie Inc. |
proteína de ligação capaz de se ligar a dll4 e vegf, bem como composição que a compreende como composição que a compreende
|
|
MX2015005874A
(es)
|
2012-11-09 |
2015-09-10 |
Pfizer |
Anticuerpos especificos del factor de crecimiento b derivados de plaquetas y composiciones y usos de estos.
|
|
US10034988B2
(en)
|
2012-11-28 |
2018-07-31 |
Fontem Holdings I B.V. |
Methods and devices for compound delivery
|
|
EP2934575A2
(de)
|
2012-12-19 |
2015-10-28 |
Amplimmune, Inc. |
B7-h4-spezifische antikörper sowie zusammensetzungen und verfahren zur verwendung davon
|
|
JP6359031B2
(ja)
|
2012-12-21 |
2018-07-18 |
メディミューン，エルエルシー |
抗ｈ７ｃｒ抗体
|
|
AU2013361337A1
(en)
|
2012-12-21 |
2015-07-09 |
Map Pharmaceuticals, Inc. |
8'-Hydroxy-Dihydroergotamine compounds and compositions
|
|
EP2950797B1
(de)
|
2013-02-01 |
2019-09-11 |
Glialogix, Inc. |
Zusammensetzungen sowie verfahren zur behandlung von neurodegenerativen und anderen erkrankungen
|
|
MX2015010146A
(es)
|
2013-02-08 |
2016-05-31 |
Novartis Ag |
Sitios especificos para modificar anticuerpos para hacer inmunoconjugados.
|
|
WO2014124258A2
(en)
|
2013-02-08 |
2014-08-14 |
Irm Llc |
Specific sites for modifying antibodies to make immunoconjugates
|
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
|
JP2016514130A
(ja)
|
2013-03-14 |
2016-05-19 |
ノバルティス アーゲー |
Ｎｏｔｃｈ３に対する抗体
|
|
JP6505076B2
(ja)
|
2013-03-14 |
2019-04-24 |
アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ |
Ｈｃｖ抗原−抗体組み合わせアッセイおよびこれに使用するための方法および組成物
|
|
MX2015012825A
(es)
|
2013-03-14 |
2016-06-10 |
Abbott Lab |
Anticuerpos monoclonales del dominio de union de lipido del núcleo del virus de la hepatitis c vhc.
|
|
JP2016512241A
(ja)
|
2013-03-14 |
2016-04-25 |
アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ |
改良された抗体検出のためのｈｃｖｎｓ３組換え抗原およびこの突然変異体
|
|
US9469686B2
(en)
|
2013-03-15 |
2016-10-18 |
Abbott Laboratories |
Anti-GP73 monoclonal antibodies and methods of obtaining the same
|
|
EP2968590B1
(de)
|
2013-03-15 |
2018-09-05 |
Novartis AG |
Antikörper-wirkstoff-konjugate
|
|
WO2014144280A2
(en)
|
2013-03-15 |
2014-09-18 |
Abbvie Inc. |
DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
|
|
KR20160129698A
(ko)
|
2013-05-24 |
2016-11-09 |
메디뮨 엘엘씨 |
항-b7-h5 항체 및 이의 용도
|
|
WO2014194293A1
(en)
|
2013-05-30 |
2014-12-04 |
Amplimmune, Inc. |
Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
|
|
SG10201708143QA
(en)
|
2013-06-06 |
2017-11-29 |
Pierre Fabre Médicament |
Anti-c10orf54 antibodies and uses thereof
|
|
CA2914566A1
(en)
|
2013-06-07 |
2014-12-11 |
Duke University |
Inhibitors of complement factor h
|
|
UA116479C2
(uk)
|
2013-08-09 |
2018-03-26 |
Макродженікс, Інк. |
БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
|
|
US11384149B2
(en)
|
2013-08-09 |
2022-07-12 |
Macrogenics, Inc. |
Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
|
|
EP2839842A1
(de)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bispezifische monovalente Diabodies mit Fähigkeit zur Bindung von CD123 und CD3 und Verwendungen davon
|
|
EP2840091A1
(de)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bispezifische Diabodies, die gpA33 und CD3 binden können und Anwendungen dieser
|
|
MX2016003525A
(es)
|
2013-09-17 |
2017-01-06 |
Univ Health Network (Uhn) |
Agentes dirigidos contra una interaccion cis de molecula de orientacion repulsiva a (rgma) /neogenina o balsas lipidicas y uso de los mismos en metodos de tratamiento.
|
|
US10194693B2
(en)
|
2013-09-20 |
2019-02-05 |
Fontem Holdings 1 B.V. |
Aerosol generating device
|
|
WO2015066480A1
(en)
|
2013-11-01 |
2015-05-07 |
Regents Of The University Of Minnesota |
Protein scaffolds and methods of use
|
|
CA3056647A1
(en)
|
2013-11-13 |
2015-05-21 |
Robert ARCH |
Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
|
|
WO2015084883A2
(en)
|
2013-12-02 |
2015-06-11 |
Abbvie, Inc. |
Compositions and methods for treating osteoarthritis
|
|
WO2015109212A1
(en)
|
2014-01-17 |
2015-07-23 |
Pfizer Inc. |
Anti-il-2 antibodies and compositions and uses thereof
|
|
WO2015110930A1
(en)
|
2014-01-24 |
2015-07-30 |
Pfizer Inc. |
Modified interleukin 21 receptor proteins
|
|
SG11201606714TA
(en)
|
2014-02-14 |
2016-09-29 |
Andrew S Chi |
Improved methods for the treatment of vascularizing cancers
|
|
EP3450571B1
(de)
|
2014-02-24 |
2023-04-05 |
Celgene Corporation |
Verfahren zur verwendung eines aktivators von cereblon für neuronale zellexpansion und behandlung von erkrankungen des zentralnervensystems
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
WO2015138337A1
(en)
|
2014-03-09 |
2015-09-17 |
Abbvie, Inc. |
Compositions and methods for treating rheumatoid arthritis
|
|
WO2015138615A2
(en)
|
2014-03-12 |
2015-09-17 |
Irm Llc |
Specific sites for modifying antibodies to make immunoconjugates
|
|
TWI684600B
(zh)
|
2014-03-21 |
2020-02-11 |
美商艾伯維有限公司 |
抗－ｅｇｆｒ抗體及抗體藥物結合物
|
|
WO2015175874A2
(en)
|
2014-05-16 |
2015-11-19 |
Medimmune, Llc |
Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
|
|
SG11201609917PA
(en)
|
2014-05-29 |
2016-12-29 |
Macrogenics Inc |
Tri-specific binding molecules and methods of use thereof
|
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
|
WO2016020791A1
(en)
|
2014-08-05 |
2016-02-11 |
Novartis Ag |
Ckit antibody drug conjugates
|
|
US9982045B2
(en)
|
2014-08-12 |
2018-05-29 |
Novartis Ag |
Anti-CDH6 antibody drug conjugates
|
|
JP6839075B2
(ja)
|
2014-09-26 |
2021-03-03 |
マクロジェニクス，インコーポレーテッド |
Ｃｄ１９及びｃｄ３に結合できる二重特異性１価ダイアボディ並びにその使用
|
|
US20170304459A1
(en)
|
2014-10-10 |
2017-10-26 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhalation delivery of conjugated oligonucleotide
|
|
US10766959B2
(en)
|
2014-12-11 |
2020-09-08 |
Pierre Fabre Medicament |
Anti-C10ORF54 antibodies and uses thereof
|
|
WO2016094881A2
(en)
|
2014-12-11 |
2016-06-16 |
Abbvie Inc. |
Lrp-8 binding proteins
|
|
WO2016092508A1
(en)
|
2014-12-12 |
2016-06-16 |
Massachusetts General Hospital |
Treatment of breast cancer brain metastases
|
|
WO2016118921A1
(en)
|
2015-01-24 |
2016-07-28 |
Abbvie, Inc. |
Compositions and methods for treating psoriatic arthritis
|
|
TWI688572B
(zh)
|
2015-01-26 |
2020-03-21 |
美商宏觀基因股份有限公司 |
包含dr5-結合結構域的多價分子
|
|
WO2016120828A1
(en)
|
2015-01-30 |
2016-08-04 |
Novartis Ag |
Treatment of breast cancer by m-csf antagonist
|
|
BR112017015880A2
(pt)
|
2015-03-03 |
2018-07-31 |
Kymab Ltd |
anticorpos, usos e métodos
|
|
DK3303395T3
(da)
|
2015-05-29 |
2020-01-27 |
Abbvie Inc |
Anti-cd40-antistoffer og anvendelser deraf
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
|
|
US20190194315A1
(en)
|
2015-06-17 |
2019-06-27 |
Novartis Ag |
Antibody drug conjugates
|
|
US11066481B2
(en)
|
2015-07-23 |
2021-07-20 |
The Regents Of The University Of California |
Antibodies to coagulation factor XIa and uses thereof
|
|
SG10201906059VA
(en)
|
2015-07-30 |
2019-08-27 |
Macrogenics Inc |
Pd-1-binding molecules and methods of use thereof
|
|
CA2998183A1
(en)
|
2015-09-11 |
2017-03-16 |
AbbVie Deutschland GmbH & Co. KG |
Methods for treating relapsing forms of multiple sclerosis
|
|
US9862760B2
(en)
|
2015-09-16 |
2018-01-09 |
Novartis Ag |
Polyomavirus neutralizing antibodies
|
|
JP7320944B2
(ja)
|
2015-10-08 |
2023-08-04 |
マクロジェニクス，インコーポレーテッド |
Ｂ７‐ｈ３に特異的に結合する分子及びｐｄ‐１に特異的に結合する分子
|
|
WO2017070561A1
(en)
|
2015-10-23 |
2017-04-27 |
Pfizer Inc. |
Anti-il-2 antibodies and compositions and uses thereof
|
|
MA44334A
(fr)
|
2015-10-29 |
2018-09-05 |
Novartis Ag |
Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
|
|
WO2017096051A1
(en)
|
2015-12-02 |
2017-06-08 |
Stcube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
|
|
US11253590B2
(en)
|
2015-12-02 |
2022-02-22 |
Stsciences, Inc. |
Antibodies specific to glycosylated BTLA (B- and T- lymphocyte attenuator)
|
|
EP3389714A4
(de)
|
2015-12-14 |
2019-11-13 |
MacroGenics, Inc. |
Bispezifische moleküle mit immunreaktivität mit pd-1 und ctla-4 und verfahren zur verwendung davon
|
|
WO2017125897A1
(en)
|
2016-01-21 |
2017-07-27 |
Novartis Ag |
Multispecific molecules targeting cll-1
|
|
WO2017142928A1
(en)
|
2016-02-17 |
2017-08-24 |
Macrogenics, Inc. |
Ror1-binding molecules, and methods of use thereof
|
|
CN114272389B
(zh)
|
2016-03-02 |
2023-04-18 |
卫材研究发展管理有限公司 |
基于艾日布林的抗体-药物偶联物和使用方法
|
|
WO2017180813A1
(en)
|
2016-04-15 |
2017-10-19 |
Macrogenics, Inc. |
Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof
|
|
US20170349653A1
(en)
|
2016-06-01 |
2017-12-07 |
Abbvie Inc. |
Methods for treating spinal cord injury and pain
|
|
JP2019524651A
(ja)
|
2016-06-08 |
2019-09-05 |
アッヴィ・インコーポレイテッド |
抗ｃｄ９８抗体及び抗体薬物コンジュゲート
|
|
CN109563167A
(zh)
|
2016-06-08 |
2019-04-02 |
艾伯维公司 |
抗b7-h3抗体和抗体药物偶联物
|
|
LT3458479T
(lt)
|
2016-06-08 |
2021-02-25 |
Abbvie Inc. |
Anti-b7-h3 antikūnai ir antikūnų vaisto konjugatai
|
|
WO2017220990A1
(en)
|
2016-06-20 |
2017-12-28 |
Kymab Limited |
Anti-pd-l1 antibodies
|
|
EP3487521A4
(de)
|
2016-07-21 |
2020-07-01 |
Emory University |
Ebolavirus-antikörper und binder daraus
|
|
WO2018075865A1
(en)
|
2016-10-21 |
2018-04-26 |
Glialogix, Inc. |
Compositions for the treatment of neurodegenerative diseases
|
|
EP3534947A1
(de)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antikörper, kombinationen mit antikörpern, biomarker, verwendungen und verfahren
|
|
JP7274417B2
(ja)
|
2016-11-23 |
2023-05-16 |
イミュノア・セラピューティクス・インコーポレイテッド |
４－１ｂｂ結合タンパク質及びその使用
|
|
AU2017377993A1
(en)
|
2016-12-13 |
2019-07-04 |
Emory University |
Polypeptides for managing viral infections
|
|
JOP20190155A1
(ar)
|
2016-12-21 |
2019-06-23 |
Novartis Ag |
مترافقات عقار جسم مضاد لإزالة خلايا جذعية مكونة للدم
|
|
IL267589B1
(en)
|
2016-12-23 |
2024-07-01 |
Macrogenics Inc |
ADAM9 binding molecules and methods of their use
|
|
US11680101B2
(en)
|
2017-01-27 |
2023-06-20 |
Kymab Limited |
Anti-OPG antibodies
|
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
|
CA3064697A1
(en)
|
2017-04-19 |
2018-10-25 |
Bluefin Biomedicine, Inc. |
Anti-vtcn1 antibodies and antibody drug conjugates
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
US10865238B1
(en)
|
2017-05-05 |
2020-12-15 |
Duke University |
Complement factor H antibodies
|
|
EP3630834A1
(de)
|
2017-05-31 |
2020-04-08 |
STCube & Co., Inc. |
Verfahren zur behandlung von krebs mit antikörpern und molekülen, die immunspezifisch an btn1a1 binden
|
|
KR20200015602A
(ko)
|
2017-05-31 |
2020-02-12 |
주식회사 에스티큐브앤컴퍼니 |
Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도
|
|
CN110997724A
(zh)
|
2017-06-06 |
2020-04-10 |
斯特库伯株式会社 |
使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
|
|
EP3717516A1
(de)
|
2017-12-01 |
2020-10-07 |
Pfizer Inc |
Anti-cxcr5-antikörper sowie zusammensetzungen und verwendungen davon
|
|
US11433132B2
(en)
|
2017-12-01 |
2022-09-06 |
Novartis Ag |
Polyomavirus neutralizing antibodies
|
|
CA3090322A1
(en)
|
2018-02-12 |
2019-08-15 |
Diabetes-Free, Inc. |
Improved antagonistic anti-human cd40 monoclonal antibodies
|
|
BR112020017701A2
(pt)
|
2018-03-12 |
2020-12-29 |
Zoetis Services Llc |
Anticorpos anti-ngf e métodos dos mesmos
|
|
EP3774863A1
(de)
|
2018-03-29 |
2021-02-17 |
Pfizer Inc |
Lfa3-varianten sowie zusammensetzungen und verwendungen davon
|
|
US10640576B2
(en)
|
2018-04-10 |
2020-05-05 |
Y-Biologics Inc. |
Cell engaging binding molecules
|
|
EP3801766A1
(de)
|
2018-05-31 |
2021-04-14 |
Novartis AG |
Hepatitis-b-antikörper
|
|
EP3801632A1
(de)
|
2018-06-01 |
2021-04-14 |
Eisai R&D Management Co., Ltd. |
Spleissmodulator-antikörper-wirkstoff-konjugate und verfahren zur verwendung
|
|
CN112384531B
(zh)
|
2018-06-01 |
2024-05-14 |
诺华股份有限公司 |
针对bcma的结合分子及其用途
|
|
UY38265A
(es)
|
2018-06-20 |
2020-01-31 |
Novartis Ag |
Conjugados anticuerpo droga para ablación de células madre hematopoyéticas
|
|
CA3111339A1
(en)
|
2018-07-10 |
2020-01-16 |
Rush University Medical Center |
Use of immunomodulators to control infection and stimulate healing in normal and diabetic wounds
|
|
BR112021000934A2
(pt)
|
2018-07-20 |
2021-04-27 |
Pierre Fabre Medicament |
receptor para vista
|
|
SG11202100888WA
(en)
|
2018-09-07 |
2021-02-25 |
Pfizer |
Anti-avb8 antibodies and compositions and uses thereof
|
|
WO2020053742A2
(en)
|
2018-09-10 |
2020-03-19 |
Novartis Ag |
Anti-hla-hbv peptide antibodies
|
|
WO2020102454A1
(en)
|
2018-11-13 |
2020-05-22 |
Regents Of The University Of Minnesota |
Cd40 targeted peptides and uses thereof
|
|
JP7463366B2
(ja)
|
2018-11-20 |
2024-04-08 |
タケダ ワクチン，インコーポレイテッド |
新規の抗ジカウイルス抗体及びその使用
|
|
CN113271981A
(zh)
|
2018-12-13 |
2021-08-17 |
卫材R&D管理有限公司 |
荷伯希二烯抗体-药物缀合物及使用方法
|
|
WO2020128863A1
(en)
|
2018-12-19 |
2020-06-25 |
Novartis Ag |
Anti-tnf-alpha antibodies
|
|
JOP20210159A1
(ar)
|
2018-12-21 |
2023-01-30 |
Novartis Ag |
أجسام مضادة لـ pmel17 ومترافقات منها
|
|
US20220062391A1
(en)
|
2019-01-16 |
2022-03-03 |
University Of Rochester |
Enhancing epithelial or endothelial barrier function
|
|
EP3936501A4
(de)
|
2019-03-08 |
2022-11-09 |
ABTIS Co., Ltd. |
Ortsspezifische antikörper-konjugation und antikörper-wirkstoff-konjugat als spezifisches beispiel dafür
|
|
BR112021021775A2
(pt)
|
2019-04-29 |
2022-01-04 |
Insmed Inc |
Composições de pó seco de pró-fármacos de treprostinil e métodos de uso destas
|
|
KR20220010527A
(ko)
|
2019-05-20 |
2022-01-25 |
노파르티스 아게 |
친수성 기를 포함하는 링커를 갖는 항체 약물 콘쥬게이트
|
|
EP4041767A1
(de)
|
2019-09-26 |
2022-08-17 |
StCube & Co. |
Spezifische antikörper gegen glykosiertes ctla-4 und verfahren zur verwendung davon
|
|
WO2021072277A1
(en)
|
2019-10-09 |
2021-04-15 |
Stcube & Co. |
Antibodies specific to glycosylated lag3 and methods of use thereof
|
|
MX2022005221A
(es)
|
2019-11-07 |
2022-06-08 |
Eisai R&D Man Co Ltd |
Conjugados de anticuerpo y farmaco de eribulina anti-mesotelina y metodos de uso.
|
|
WO2021148983A1
(en)
|
2020-01-24 |
2021-07-29 |
Pfizer Inc. |
Anti-e-selectin antibodies, compositions and methods of use
|
|
WO2021202463A1
(en)
|
2020-03-30 |
2021-10-07 |
Danisco Us Inc |
Anti-rsv antibodies
|
|
US20230203191A1
(en)
|
2020-03-30 |
2023-06-29 |
Danisco Us Inc |
Engineered antibodies
|
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
|
WO2021220218A1
(en)
|
2020-05-01 |
2021-11-04 |
Novartis Ag |
Immunoglobulin variants
|
|
EP4143236A1
(de)
|
2020-05-01 |
2023-03-08 |
Novartis AG |
Manipulierte immunglobuline
|
|
EP4157455A1
(de)
|
2020-05-29 |
2023-04-05 |
Universität zu Köln |
Neutralisierende antikörper gegen sars-assoziiertes coronavirus
|
|
KR20230020441A
(ko)
|
2020-06-05 |
2023-02-10 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
항-bcma 항체-약물 컨쥬게이트 및 이용 방법
|
|
PE20240589A1
(es)
|
2020-10-09 |
2024-03-21 |
Pfizer |
ANTICUERPOS CD1a Y SU USO
|
|
GB202017058D0
(en)
|
2020-10-27 |
2020-12-09 |
Kymab Ltd |
Antibodies and uses thereof
|
|
IL302569A
(en)
|
2020-11-06 |
2023-07-01 |
Novartis Ag |
CD19 binding molecules and their uses
|
|
JP2023547499A
(ja)
|
2020-11-06 |
2023-11-10 |
ノバルティス アーゲー |
抗体Ｆｃ変異体
|
|
AU2021374083A1
(en)
|
2020-11-06 |
2023-06-01 |
Novartis Ag |
Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
|
|
EP4251648A2
(de)
|
2020-11-24 |
2023-10-04 |
Novartis AG |
Anti-cd48-antikörper, antikörper-wirkstoff-konjugate und verwendungen davon
|
|
EP4259200A1
(de)
|
2020-12-11 |
2023-10-18 |
Boehringer Ingelheim International GmbH |
Formulierung für mehrzweckanwendung
|
|
AR124681A1
(es)
|
2021-01-20 |
2023-04-26 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
|
GB202101125D0
(en)
|
2021-01-27 |
2021-03-10 |
Kymab Ltd |
Antibodies and uses thereof
|
|
CA3235132A1
(en)
|
2021-04-16 |
2022-10-20 |
Novartis Ag |
Antibody drug conjugates and methods for making thereof
|
|
EP4423123A1
(de)
|
2021-10-28 |
2024-09-04 |
Novartis AG |
Manipulierte fc-varianten
|
|
GB202117111D0
(en)
|
2021-11-26 |
2022-01-12 |
Kymab Ltd |
Antibodies for use as therapeutics against bacterial infections
|
|
EP4190810A1
(de)
|
2021-12-01 |
2023-06-07 |
Universität zu Köln |
Neutralisierende antikörper gegen das mit sars-verwandte coronavirus
|
|
WO2023099688A1
(en)
|
2021-12-01 |
2023-06-08 |
Universität Zu Köln |
Neutralizing antibodies against sars-related coronavirus
|
|
WO2023150747A1
(en)
|
2022-02-07 |
2023-08-10 |
Insmed Incorporated |
Dry powder compositions of bedaquiline and salts and methods of use thereof
|
|
AU2023259761A1
(en)
|
2022-04-26 |
2024-09-26 |
Novartis Ag |
Multispecific antibodies targeting il-13 and il-18
|
|
WO2024013727A1
(en)
|
2022-07-15 |
2024-01-18 |
Janssen Biotech, Inc. |
Material and methods for improved bioengineered pairing of antigen-binding variable regions
|
|
WO2024028732A1
(en)
|
2022-08-05 |
2024-02-08 |
Janssen Biotech, Inc. |
Cd98 binding constructs for treating brain tumors
|
|
WO2024028731A1
(en)
|
2022-08-05 |
2024-02-08 |
Janssen Biotech, Inc. |
Transferrin receptor binding proteins for treating brain tumors
|
|
WO2024127366A1
(en)
|
2022-12-16 |
2024-06-20 |
Pheon Therapeutics Ltd |
Antibodies to cub domain-containing protein 1 (cdcp1) and uses thereof
|
|
US20240294651A1
(en)
|
2023-01-30 |
2024-09-05 |
Kymab Limited |
Antibodies
|
|
WO2024175802A2
(en)
|
2023-02-24 |
2024-08-29 |
Universität Zu Köln |
SARS-CoV-2 NEUTRALIZING ANTIBODIES
|